Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine.

The Canadian Journal of Cardiology
Sanjay Kaul

Abstract

A noninferiority trial is designed to show that the new treatment is not unacceptably worse than the standard treatment by more than a predefined noninferiority margin. These trials are typically performed when standard placebo-controlled trials are considered to be unethical or impractical and the new treatment offers advantages over the existing standard treatment in terms of safety, convenience, or cost. Given that noninferiority trials are being performed with increasing frequency in cardiovascular applications, it is important to understand their complex trial design and analysis. This narrative review aims to provide readers with a detailed perspective on the goals, characteristics, design, and analysis of noninferiority trials. Trials designed to show noninferiority require an appropriate reference population, a proven standard treatment and dose, an appropriate margin of noninferiority that is statistically justifiable (based on historical placebo-controlled trials evaluating standard treatment effect) and clinically reasonable (choosing the fraction of the effect of the standard drug that should be "preserved" by the new drug), a high level of adherence to treatment, and adequate statistical power to reliably conclude ...Continue Reading

References

Apr 29, 2000·Annals of Internal Medicine·W L GreeneA R Feinstein
Jun 23, 2004·Journal of Biopharmaceutical Statistics·Steven M Snapinn
Dec 6, 2005·Journal of the American College of Cardiology·Sanjay KaulWilliam S Weintraub
Jul 5, 2006·Annals of Internal Medicine·Sanjay Kaul, George A Diamond
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
Feb 21, 2009·The New England Journal of Medicine·Patrick W SerruysUNKNOWN SYNTAX Investigators
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Jul 30, 2010·Clinical Pharmacology and Therapeutics·G WanggeM J Knol
Sep 3, 2010·Statistics in Medicine·Siobhan Everson-Stewart, Scott S Emerson
Apr 6, 2011·The New England Journal of Medicine·Seung-Jung ParkKi Bae Seung
Apr 6, 2011·The New England Journal of Medicine·Ted FeldmanUNKNOWN EVEREST II Investigators
May 5, 2011·Trials·Jennifer Schumi, Janet T Wittes
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
May 9, 2012·European Heart Journal·Stuart J HeadA Pieter Kappetein
Dec 27, 2012·JAMA : the Journal of the American Medical Association·Gilda PiaggioUNKNOWN CONSORT Group
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Nov 18, 2014·The New England Journal of Medicine·Laura MauriUNKNOWN DAPT Study Investigators
Jan 27, 2015·European Heart Journal·Stefanie Schulz-SchüpkeUNKNOWN Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Elut
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Oct 13, 2015·The New England Journal of Medicine·Stephen G EllisUNKNOWN ABSORB III Investigators
Nov 1, 2016·The New England Journal of Medicine·Gregg W StoneUNKNOWN EXCEL Trial Investigators
Mar 21, 2017·The New England Journal of Medicine·Matthias GötbergUNKNOWN iFR-SWEDEHEART Investigators
Oct 5, 2017·The New England Journal of Medicine·Laura Mauri, Ralph B D'Agostino
Nov 7, 2017·Journal of the American College of Cardiology·Vivek Y ReddyUNKNOWN PREVAIL and PROTECT AF Investigators
Aug 31, 2018·European Heart Journal·Franz-Josef NeumannUNKNOWN ESC Scientific Document Group
Jun 11, 2019·Circulation·Behnood BikdeliHarlan M Krumholz
Sep 27, 2019·The New England Journal of Medicine·Roxana MehranC Michael Gibson
Sep 29, 2019·The New England Journal of Medicine·Gregg W StoneUNKNOWN EXCEL Trial Investigators
Jun 27, 2020·Journal of the American College of Cardiology·Pavel OsmancikUNKNOWN PRAGUE-17 Trial Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

The New England Journal of Medicine
Peter DoshiJohn H Powers
The New England Journal of Medicine
Silvio Garattini, Vittorio Bertele’
The New England Journal of Medicine
Stefan Lange
The New England Journal of Medicine
Laura Mauri, Ralph B D’Agostino
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Fabio AngeliGianpaolo Reboldi
© 2021 Meta ULC. All rights reserved